课题基金 / 基金详情

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,MULTIPLE-DOSE SAFETY STUDY OF GEM91

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,MULTIPLE-DOSE SAFETY STUDY OF GEM91
GEM91 的随机、双盲、安慰剂对照、多剂量安全性研究
批准号：
6245112
负责人：
MICHAEL F GIORDANO
金额：
$5.36万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-24 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6245112
关键词：
AIDS therapy HIV infections antiAIDS agent antiviral agents clinical research clinical trial phase I drug screening /evaluation genetic translation human immunodeficiency virus human subject human therapy evaluation messenger RNA oligonucleotides pharmacokinetics placebos

项目摘要

项目成果

MICHAEL F GIORDANO的其他基金

相似基金

相关文献

中文摘要
翻译
这是GEM-91的Ib期安全性和耐受性研究
英文摘要
This is a Phase Ib safety and tolerability study of GEM-91, a 25- meroligodeoxy-nucleotide which binds to the mRNA of HIV, thus terminating translation and potentially having anti-HIV effect, 15 HIV-infected volunteers will receive GEM 91 or placebo for 14 days followed by 14 days of open label GEM 91 to assess the drugs safety, tolerability, pharmacokinetics, and anti-viral effect.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE I/II MULTIPLE DOSE STUDY OF ZINTEVIR IN HIV-1 PATIENTS
PHASE I/II MULTIPLE DOSE STUDY OF ZINTEVIR IN HIV-1 PATIENTS
COMPARISON OF SAFETY & EFFICACY OF RS 79070 & ORAL PRODRUG VS IV GANCICLOVIR
PHASE I/II MULTIPLE DOSE STUDY OF ZINTEVIR IN HIV-1 PATIENTS
海外基金